The Minimalist Trial-2

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the

Trial Details

NCT ID
NCT06702033
Phase
PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Radiation therapy
  • Cisplatin
  • Surgery
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Fargo, North Dakota, United States|46.87719,-96.7898
  • Sioux Falls, South Dakota, United States|43.54369,-96.72796

Key Eligibility Criteria

  • Histologically or cytologically confirmed HPV-related, clinical stages I-II OPSCC (8th edition of AJCC/UICC Staging Manual) or HPV-related neck nod…
  • Planned resection of the primary tumor site by a transoral approach (TORS, TLM, or conventional surgery).
  • Planned unilateral or contralateral selective neck dissection.
  • ECOG PS 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →